Sign in

Jeff Huber

Director at Summit Therapeutics
Board

About Jeff Huber

Jeff Huber (age 56) has served as an independent director of Summit Therapeutics since June 2024; he is Audit Committee Chair and designated the Audit Committee financial expert. He is co-founder and Managing Director of Triatomic Capital (since 2022), previously Vice Chairman and Founding CEO of GRAIL (2016–2021; Founding CEO 2016–2017), and held senior roles at Alphabet/Google (SVP, 2003–2016), eBay (VP Architecture & Systems, 2001–2003), and Excite@Home; he holds a B.S. in Computer Engineering (University of Illinois) and an MBA (Harvard). The Board has determined Huber is independent under Nasdaq rules.

Past Roles

OrganizationRoleTenureCommittees/Impact
Triatomic Capital Private LPCo-founder & Managing DirectorSince 2022Private investing firm leadership
GRAIL, Inc.Vice Chairman; Founding CEO2016–2021; 2016–2017Led early cancer detection platform
Alphabet Inc. (Google)Senior Vice President2003–2016Executive leadership in technology scale-up
eBay Inc.VP, Architecture & Systems Development2001–2003Platform architecture
Excite@HomeSVP, EngineeringNot disclosedSenior engineering leadership

External Roles

OrganizationRoleTenureCommittees/Impact
Electronic Arts Inc. (public)DirectorCurrentBoard oversight
Upstart Holdings Inc. (public)DirectorCurrentBoard oversight
Mammoth Bio; d‑Matrix; Manifold Bio; Openwater; Genalyte; Weta Digital (private)Board memberNot disclosedTech/biotech innovation networks
Aldevron (private)Director2019–2021Biotech manufacturing governance
Zapata Computing Holdings Inc. (public)Director2021–2024AI/quantum software oversight

Board Governance

  • Independence: Board determined Huber is independent under Nasdaq rules.
  • Committee assignments: Audit Committee Chair; Audit members are Huber (Chair), Booth, Ronaghi; Huber qualifies as Audit Committee financial expert.
  • Attendance: In 2024, the Board held 2 meetings; each director attended at least 75% of board and applicable committee meetings; all current Board members attended the 2024 annual meeting.
  • Committee activity: 2024 meetings—Audit: 6; Compensation: 1; Nominating & Corporate Governance: 0.
  • Lead Independent Director: Kenneth A. Clark is appointed Lead Independent Director.
  • Controlled company status: Summit is a “controlled company” under Nasdaq due to majority voting power held by Robert W. Duggan; while not currently using all exemptions, the company has relied on some and may do so in the future.
  • Insider trading policy: Prohibits short sales, derivatives (puts/calls), and direct hedging transactions in company securities.

Fixed Compensation

ComponentAmount/TermsNotes
Annual Board retainer (cash)$49,900Paid quarterly
Committee membership fee (each committee)$6,500Annual, per committee
Committee Chair feesAudit: $36,700; Compensation: $13,000; Nominating: $13,000Annual
2024 cash fees actually earned (Huber)$39,055Reported in 2024 Director Compensation

Performance Compensation

Equity ComponentGrant detailVesting/Terms2024 Value/Counts
Annual director option grant35,000 optionsVests in four equal quarterly installments; strike = FMV at grantProgram terms
New director grant (Huber, 2024)200,000 optionsVests in four equal annual installments; first tranche at 1-year anniversary; strike = FMV at grantProgram terms
Retainer Option ElectionCash-to-option conversion at 2.0x multiplier; annual awardVests quarterly; 10-year termProgram terms
2024 option award (Huber)Option Awards fair value: $1,507,113
Options outstanding (Huber, 12/31/2024)217,883Exercisable: 17,883

Other Directorships & Interlocks

EntityTypeRelationshipNote
Electronic Arts Inc.PublicDirectorCurrent role
Upstart Holdings Inc.PublicDirectorCurrent role
GRAIL, Inc.Private (historical)Huber: Founding CEO/Vice Chair; Ronaghi: Co-founderHistorical overlap with fellow SMMT director Mostafa Ronaghi (interlock signal)

Expertise & Qualifications

  • Audit Committee financial expert designation; financial literacy confirmed by the Board.
  • Deep technology and healthcare leadership background spanning large-scale platforms and life sciences innovation.
  • Education: B.S. in Computer Engineering (University of Illinois); MBA (Harvard Business School).

Equity Ownership

HolderShares OwnedOptions exercisable within 60 daysTotal Beneficial Ownership% of Class
Jeff Huber (as of April 15, 2025)50,05226,63376,685<1%
Jeff Huber (as of Dec 31, 2024)Options outstanding: 217,883; Exercisable: 17,883

Governance Assessment

  • Strengths: Independent audit chair with financial expert status; Audit Committee met six times in 2024 indicating robust oversight; clear prohibitions on hedging/derivatives in Insider Trading Policy; Lead Independent Director structure in place.
  • Alignment: Director pay is heavily equity-oriented for Huber in 2024 (cash $39,055 versus option award fair value $1,507,113), and program allows conversion of cash retainers into options (2.0x multiplier), increasing ownership alignment.
  • Attendance & engagement: Board convened 2 times in 2024; all directors met at least 75% attendance, and Audit Committee met 6 times under Huber’s chairmanship—solid engagement for audit oversight.
  • Potential conflicts/related-party exposure: No related-party transactions involving Huber are disclosed; related-party items center on Duggan, Zanganeh (bridge notes, warrants, office subleases), Xia/Akeso (license & payments), Soni (share purchases), and Clark/WSGR (legal services).
  • Risk indicators and red flags:
    • Controlled company status may reduce certain Nasdaq governance protections; the company may rely on exemptions in the future (investor vigilance warranted).
    • Pending derivative litigation related to December 2022 bridge financing notes (fiduciary duty claims) creates governance overhang; Huber is part of the Board’s oversight environment as Audit Chair. Defendants plan to move to dismiss.
    • Personal ownership remains small (<1%), which is typical for outside directors but provides limited “skin-in-the-game” relative to controlling shareholders.
  • Shareholder signals: Strong say-on-pay support (≈97% approval in 2024) provides a positive governance sentiment backdrop, though not director-specific.